These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24250664)

  • 1. The effect of capital structure on the profitability of pharmaceutical companies the case of iran.
    Mohammadzadeh M; Rahimi F; Rahimi F; Aarabi SM; Salamzadeh J
    Iran J Pharm Res; 2013; 12(3):573-7. PubMed ID: 24250664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis.
    Varmaghani M; Meshkini AH; Farzadfar F; Yousefi M; Yaghoubifard S; Varahrami V; Darzi ER; Anabi M; Kebriaeezadeh A; Zekri HS
    J Res Pharm Pract; 2015; 4(2):51-6. PubMed ID: 25984541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of working capital management for hospital profitability: evidence from bond-issuing, not-for-profit U.S. hospitals.
    Rauscher S; Wheeler JR
    Health Care Manage Rev; 2012; 37(4):339-46. PubMed ID: 21712724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing enterprise asset structure and profitability using cloud computing and strategic management accounting.
    Shi W
    PLoS One; 2021; 16(9):e0257826. PubMed ID: 34591883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profitability determinants of the natural stone industry: Evidence from Spain and Italy.
    Zambrano Farías FJ; Martínez MDCV; Martín-Cervantes PA
    PLoS One; 2022; 17(12):e0276885. PubMed ID: 36477461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures.
    Lee M; Choi M
    Osong Public Health Res Perspect; 2015 Oct; 6(5):302-9. PubMed ID: 26730355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the education level of the CEO and CFO affect the profitability of real estate and construction companies? Evidence from Vietnam.
    Nguyen TTC; Nguyen CV
    Heliyon; 2024 Apr; 10(7):e28376. PubMed ID: 38590899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the Interaction Effect between the Intensity of Government Low-Carbon Subsidies and the Growth Ability of Green and Low-Carbon Emerging Enterprises.
    Chen L; Huang J
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organizational performance, Marketing strategy, and Financial strategic alignment: an empirical study on Iranian pharmaceutical firms.
    Mohammadzadeh M; Aarabi SM; Salamzadeh J
    Daru; 2013 Aug; 21(1):65. PubMed ID: 23915467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wise Investment? Modeling Industry Profitability and Risk of Targeted Chemotherapy for Incurable Solid Cancers.
    Conter HJ; Chu QSC
    J Oncol Pract; 2012 Mar; 8(2):69. PubMed ID: 29447097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profitability and risk-return comparison across health care industries, evidence from publicly traded companies 2010-2019.
    Bai G; Rajgopal S; Srivastava A; Zhao R
    PLoS One; 2022; 17(11):e0275245. PubMed ID: 36383519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
    Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
    Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Analysis for Chinese and US-listed Pharmaceutical Companies by the LightGBM Algorithm.
    Zheng W; Li J; Wang Y; Ye Z; Zhong H; Kot HW; Ouyang D; Chan G
    Curr Comput Aided Drug Des; 2023; 19(6):405-415. PubMed ID: 36703589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in asset structure between not-for-profit and investor-owned hospitals.
    Song PH; Reiter KL
    Med Care Res Rev; 2010 Dec; 67(6):694-706. PubMed ID: 20519429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Decomposition of Hospital Profitability: An Application of DuPont Analysis to the US Market.
    Turner J; Broom K; Elliott M; Lee JF
    Health Serv Res Manag Epidemiol; 2015; 2():2333392815590397. PubMed ID: 28462258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and non-economic determinants of Iranian pharmaceutical companies' financial performance: an empirical study.
    Masoumi M; Ebadi Fard Azar F; RezaPour A; Mehrara M
    BMC Health Serv Res; 2019 Dec; 19(1):1011. PubMed ID: 31888627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.